Skip to content

Mepitel Film Breast

The Tolerability of Mepitel Film for the Prevention of Radiation Dermatitis in Breast Cancer Patients in Hot Weather: A Feasibility Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07729423
Enrollment
60
Registered
2026-07-27
Start date
2025-11-12
Completion date
2029-06-30
Last updated
2026-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Radiation Dermatitis

Keywords

dermatitis, radiation dermatitis, breast cancer, Mepitel Film

Brief summary

Primary Objective To examine the tolerability of Mepitel Film in the prevention of RD patients undergoing whole breast or chest wall RT in the hot and humid weather in Singapore Secondary Objectives To evaluate the incidence of acute radiation dermatitis, quality of life, satisfaction, and cost analysis of Mepitel Film use.

Detailed description

This prospective, observational feasibility study will enroll 60 breast cancer patients, divided into two cohorts: 30 receiving local breast RT and 30 receiving chest wall RT post-mastectomy. We hypothesize that Mepitel Film will be well-tolerated and effective in preventing severe RD (Grade ≥2) in this population, with results compared to published data from Western countries. Previous randomized controlled trials (RCTs) conducted in regions with low humidity and cool temperatures have raised concerns about film adherence and cost in tropical climates. Therefore, assessing the efficacy of Mepitel Film in a hot and humid environment is warranted.

Interventions

None listed

Sponsors

National University Hospital, Singapore
Lead SponsorOTHER
Molnlycke Health Care AB
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Age ≥ 21 years old (legal age of maturity in Singapore) * Male or female * Informed consent * Patients have undergone a mastectomy with or without reconstruction or breast-conserving surgery. * Histological confirmation of breast carcinoma (invasive or in situ carcinoma) * Patients are scheduled to receive hypofractionated (40Gy in 15 daily fractions or 26Gy in 5 daily fractions) photon-based RT * Patient treated with or without tissue the addition of equivalent bolus and/or boost. * Can communicate in English or be aided by a translator.

Exclusion criteria

* Prior RT to any portion of the planned treatment site. * Patients will receive partial breast external beam RT, proton beam therapy, or brachytherapy. * Patients with active rash, pre-existing dermatitis, or other conditions within the treatment area may make skin assessment for the study difficult per treating physician discretion. * Known history of adhesive, tape or silicon allergy or sensitivity. * Concomitant cytotoxic chemotherapy * Bilateral breast pathology requiring concurrent bilateral breast or chest wall RT. * Current inflammatory breast cancer or gross dermal involvement at initiation of RT. * Patient has a Karnofsky Performance Status score \<60.

Design outcomes

Primary

MeasureTime frame
Frequency of total replacement of Mepitel Film or "touch-up" when compared with the data from the RCT in Ontario, CanadaFrom first day RT to the 2 weeks post RT

Secondary

MeasureTime frame
Frequency and severity of patient reported pruritis in SSA and RISRAS related to use of Mepitel Film when compared with the data from the RCT in Ontario, CanadaFrom enrollment to the 3 months post RT
Incidence of ARD grades 2 to 3, as defined by the CTCAE V5 assessed by HCPFrom enrollment to the 2 weeks post RT
Patient-reported skin-related symptoms using the Skin Symptom Assessment (SSA)From enrollment to the end of study (2 years post RT)
HCP reported SSAFrom enrollment to the end of study (2 years post RT)
Incidence of moist desquamation assessed by HCPFrom enrollment to 2 weeks post RT
Radiation-Induced Skin Reaction Assessment Scale (RISRAS) assessed by patient and HCPFrom enrollment to 3 months post RT
Blinded HCP-assessed mRISRAS scores from blinded grading of photographs taken at the end of RTEnd of RT treatment
Photographs with EORTC-BCRSFrom enrollment to the end of study (2 years post RT)
Patient-reported QOL using the Skindex-16From enrollment to the end of study (2 years post RT)
Patient satisfaction with Mepitel Film as assessed by the patient satisfaction questionnaire3 months post RT
HCP satisfaction with Mepitel Film as assessed by the HCP satisfaction questionnaire3 months post RT
Cost analysis of Mepitel Film for prevention of RD (evaluation and calculation of Mepitel Film usage and financial cost using Film Integrity Assessment)From first day RT to the 2 weeks post RT

Countries

Singapore

Contacts

CONTACTShing Fung Lee, MBBS
leesf@nuhs.edu.sg+6567726392
CONTACTQian Yee Chai, BSc
queenie_qy_chai@nuhs.edu.sg+6567723077
PRINCIPAL_INVESTIGATORWee Yao Koh, MBBS

National University Hospital, Singapore

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 28, 2026